%0 Journal Article
%A Pascual, Tomás
%A Martin, Miguel
%A Fernández-Martínez, Aranzazu
%A Paré, Laia
%A Alba, Emilio
%A Rodríguez-Lescure, Álvaro
%A Perrone, Giuseppe
%A Cortés, Javier
%A Morales, Serafín
%A Lluch, Ana
%A Urruticoechea, Ander
%A González-Farré, Blanca
%A Galván, Patricia
%A Jares, Pedro
%A Rodriguez, Adela
%A Chic, Nuria
%A Righi, Daniela
%A Cejalvo, Juan Miguel
%A Tonini, Giuseppe
%A Adamo, Barbara
%A Vidal, Maria
%A Villagrasa, Patricia
%A Muñoz, Montserrat
%A Prat, Aleix
%T A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
%D 2019
%@ 2234-943X
%U http://hdl.handle.net/10668/13987
%X Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p
%K PAM50
%K breast cancer
%K gene expression
%K intrinsic subtype
%K non-luminal
%~